Endo USA Initiates Nationwide Recall of Everolimus Tablets Due to Impurity IP-C Out-of-Specification
Endo USA, Inc. has initiated a Class III recall for 1,866 cartons of Everolimus tablets 7.5mg across the U.S. due to out-of-specification impurity IP-C. This voluntary action, stemming from manufacturing by Par Pharmaceutical, highlights critical quality control lapses. Procurement and regulatory teams must assess supply chain vulnerabilities and ensure robust quality assurance for this vital immunosuppressant.
FDA-Initiated Recall: Everolimus Tablets Fail Impurity Specifications
Endo USA, Inc. has commenced a voluntary Class III recall, identified as D-0140-2026, for specific lots of Everolimus tablets 7.5mg distributed nationwide within the United States. This significant regulatory action, initiated on October 10, 2025, stems from the product failing to meet established impurity specifications, specifically for impurity IP-C. The affected product, bearing NDC# 49884-127-91, includes 1,866 cartons of 7.5mg tablets, with each carton containing 28 tablets across four blister strips. The manufacturing entity for these tablets is Par Pharmaceutical, located in Chestnut Ridge, NY 10977, as indicated on the product description, with Par Health USA, LLC also listed as a manufacturer in FDA records. For procurement directors, this recall necessitates an immediate assessment of inventory levels and potential supply disruptions for Everolimus 7.5mg. A Class III classification suggests that the probability of adverse health consequences is low, but the presence of an out-of-specification impurity, IP-C, still represents a critical quality control lapse. Regulatory affairs heads must scrutinize the implications of such impurity failures, as they can indicate systemic issues in manufacturing processes or raw material quality. Business development executives should recognize the reputational impact on both Endo USA, Inc. and its manufacturing partner, Par Pharmaceutical, and consider how this event might influence future partnerships or market positioning for similar immunosuppressant or kinase inhibitor products. Supply chain VPs need to understand that even a Class III recall demands robust remediation and can trigger enhanced regulatory scrutiny, potentially affecting future product availability and market access.
Recalling Firm and Manufacturing Oversight: Implications for Supply Chain
Endo USA, Inc., headquartered in Malvern, PA, is the entity initiating this recall, underscoring its responsibility for the quality and safety of products distributed under its name. While Endo USA, Inc. is the recalling firm, the manufacturing of the Everolimus tablets is attributed to Par Pharmaceutical in Chestnut Ridge, NY. This distinction highlights a common but complex aspect of the pharmaceutical supply chain: the reliance on contract manufacturing organizations (CMOs). For supply chain VPs, this structure means that managing product quality extends beyond internal operations to rigorous oversight of external partners. The failure to meet impurity specifications for IP-C directly reflects on the manufacturing process at Par Pharmaceutical, but the recall burden falls on Endo USA, Inc. Procurement directors must ensure that their quality agreements with CMOs, such as Par Pharmaceutical, include stringent clauses for impurity control, batch release specifications, and comprehensive root cause analysis protocols in the event of deviations. The recall of 1,866 cartons of Everolimus tablets 7.5mg, distributed nationwide, indicates a significant breach in quality assurance that impacts patient access across the United States. Regulatory affairs heads must monitor the FDA's follow-up actions with both Endo USA, Inc. and Par Pharmaceutical, as this event could lead to increased inspections or more severe enforcement actions if the underlying quality system deficiencies are not adequately addressed. Business development executives should evaluate the risks associated with outsourcing critical drug manufacturing, particularly for complex molecules like Everolimus, which serve as vital immunosuppressants.
Supply Chain Vulnerability for Critical Immunosuppressants: Everolimus Impact
Everolimus, a critical molecule classified as a Kinase Inhibitor and mTOR Inhibitor Immunosuppressant, plays a vital role in therapeutic areas requiring decreased immunologic activity. The recall of Everolimus tablets 7.5mg by Endo USA, Inc. due to impurity IP-C directly impacts the supply chain for this essential medication. While the recall quantity of 1,866 cartons might seem manageable, any disruption to a critical drug like Everolimus can have cascading effects on patient care, particularly for those undergoing organ transplantation or managing specific oncological conditions where it is prescribed. The nationwide distribution pattern means that healthcare providers and pharmacies across the U.S. must now manage the logistics of returning affected lots and securing compliant product. For procurement directors, this event underscores the inherent vulnerability in relying on single-source manufacturing or distribution channels for critical drugs. The specific dosage strength of 7.5mg, with multiple NDC codes (49884-119, 49884-125, 49884-127, 49884-128) associated with the product, indicates a broader portfolio of Everolimus products under scrutiny. Supply chain VPs must prioritize mapping their entire supply network for such critical molecules, identifying potential chokepoints and developing contingency plans. Regulatory affairs heads should be prepared for increased scrutiny from healthcare providers and patient advocacy groups regarding drug quality and availability. Business development executives should consider the competitive landscape and how this recall might create opportunities or challenges for companies with robust quality systems and diversified manufacturing capabilities in the immunosuppressant market.
Mitigating Supply Chain Risk: Proactive Strategies for Procurement Teams
Given the recall of Everolimus tablets 7.5mg, procurement directors must immediately activate their risk mitigation protocols. While specific alternative suppliers are not identified in the available intelligence, the strategic imperative is to diversify sourcing for critical APIs and finished drug products. This involves a multi-pronged approach to ensure supply resilience. Firstly, conduct a thorough audit of existing supplier qualification processes, particularly for complex molecules like Everolimus, to ensure they adequately assess impurity profiles and manufacturing robustness. Secondly, initiate a proactive search for new, qualified manufacturers and distributors, focusing on those with a strong track record of FDA compliance and robust quality management systems. Supply chain VPs should recognize that qualifying a new supplier for a generic drug like Everolimus can be a lengthy and resource-intensive process, involving comprehensive due diligence, facility audits, and potentially bioequivalence studies to meet regulatory requirements. This can take 12-24 months, creating a significant lead time for securing alternative supply. Regulatory affairs heads must be engaged early in this process to navigate the complexities of regulatory filings and approvals for new sources. Business development executives should explore strategic partnerships or licensing agreements with companies that possess established manufacturing capabilities and a clear regulatory history for similar compounds. The objective is to build a resilient supply chain that can withstand unforeseen quality issues and regulatory actions, minimizing disruption to patient access and safeguarding market share.
Regulatory Scrutiny and Compliance Implications for Endo and Par Pharmaceutical
The Class III recall of Everolimus tablets 7.5mg, while not the most severe classification, nonetheless signals a significant lapse in Good Manufacturing Practices (GMP) at the manufacturing level, impacting both Endo USA, Inc. as the recalling firm and Par Pharmaceutical as the manufacturer. The specific failure to meet impurity specifications for IP-C indicates a potential deficiency in raw material control, in-process controls, or finished product testing. Regulatory affairs heads at both companies will be under pressure to conduct a thorough root cause investigation and implement comprehensive Corrective and Preventive Actions (CAPA) to address the identified issues. The FDA's classification of the recall and its ongoing status means that the agency will be closely monitoring the firm's remediation efforts. For business development executives, this event can impact future product approvals or partnerships, as regulatory compliance history is a critical factor in due diligence. Any pattern of quality issues, even if individual events are Class III, can accumulate and lead to more stringent regulatory oversight, including potential Warning Letters or Import Alerts for facilities involved in manufacturing. Procurement directors should consider the long-term implications for supplier reliability and the potential for increased costs associated with enhanced quality control measures or regulatory remediation. This recall serves as a clear reminder that maintaining robust quality systems is not merely a compliance exercise but a fundamental pillar of commercial viability and patient trust in the global chemical and life sciences industry.
Remediation Timeline and Future Outlook for Everolimus Supply
The recall of Everolimus tablets 7.5mg, initiated on October 10, 2025, and classified by the FDA on October 29, 2025, remains an ongoing event. This status indicates that Endo USA, Inc., in conjunction with its manufacturer Par Pharmaceutical, is actively engaged in the recall process, which includes notifying distributors and customers, retrieving affected product, and investigating the root cause of the impurity IP-C failure. For regulatory affairs heads, the immediate priority is to finalize the recall effectiveness checks and submit a comprehensive CAPA plan to the FDA. This plan must detail how the impurity issue will be prevented in future batches, covering aspects from raw material sourcing to manufacturing processes and final product release testing. The FDA will review these submissions and may conduct follow-up inspections at Par Pharmaceutical's facility to verify the implementation and effectiveness of the corrective actions. Supply chain VPs must anticipate potential short-term supply constraints for Everolimus 7.5mg as the affected lots are removed from the market and new, compliant batches are produced and released. The duration of this impact will depend on the speed and efficacy of the remediation efforts. Business development executives should communicate transparently with stakeholders about the steps being taken to restore full supply and maintain product quality, safeguarding market reputation. Procurement directors should leverage this period to reassess their supplier risk profiles and explore strategies for geographic diversification of manufacturing, even if not immediately applicable to this specific event. The ultimate goal is to ensure a continuous, high-quality supply of Everolimus, a critical immunosuppressant, to patients across the United States.